UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
MHRA
CompanyAlso known as: MHRA, U.K. Medicines and Healthcare products Regulatory Agency, UK Medicines and Healthcare products Regulatory Agency, U.K. Medicines and Healthcare Products Regulatory Agency, UK Medicines and Healthcare Products Regulatory Agency
Related News
Life Sciences Financing Roundup: $5.7B Buyout, Juvisé Refinancing, Biotech IPO
A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
Insmed Reports Q2 2026 Revenues of $425.5M, Raises BRINSUPRI Guidance and Peak Sales Estimates
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
Recent Cancer Research Advances Span Treatments and Biomarkers
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
UK Approves First GLP-1 Weight Loss Tablet as Semaglutide Landscape Shifts
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
EMA Bolsters Clinical Trial Transparency and Launches Vaccine Information Drive
The European Medicines Agency is enforcing clinical trial transparency and has launched a new vaccine information initiative, while a coalition of health professionals warns of suboptimal vaccination coverage across Europe. An analysis also shows that only a portion of EMA-approved medicines are available to NHS patients in England after additional assessments.
UK Biotech Funding Falls 49% as Sector Struggles to Scale Despite Industrial Strategy Priority
UK biotech equity financing fell 49% in 2025, leading to calls for a £500m pension fund injection. The UK hosts over half of Europe's advanced therapy trials, yet risks losing its life sciences status to international competition.
Regulators Warn of Hidden Drugs in Sexual Enhancement and Honey Products
Australian and US regulators have warned about sexual enhancement and honey products containing undeclared prescription medicines, prompting recalls and safety alerts. UK regulators also caution about underreported drug-herb interactions and herb-induced liver injury.
OS Therapies Achieves Global Regulatory Alignment on Phase 3 Trial Design for OST-HER2 in Osteosarcoma
OS Therapies achieved FDA, MHRA, EMA and TGA alignment on the Phase 3 design for OST-HER2 in osteosarcoma. The confirmatory trial must start before BLA grant and is expected in Q3 2026.
Mexico and Finland Cut Clinical Trial Approvals to 30 Days as EU Streamlines Rules
Mexico and Finland cut clinical trial approvals to 30 days; the EU Biotech Act proposes faster timelines and harmonized rules. Finland will also establish FinTrials to boost clinical research.